Japan Procedure Numbers for Gynecological Devices 2017 - MedPro is a new market research publication announced by Reportstack.
General Report Contents• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
Despite Japan’s preference to invest in high-end medical devices, the gynecology device market is constrained by the lack of training, diversity in alternative procedures and investment in specialty equipment. The predominant shift towards capital equipment that can be used off label across procedure types is both limiting capital equipment sales and access to preferred treatment options in 2016.
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
Despite Japan’s preference to invest in high-end medical devices, the gynecology device market is constrained by the lack of training, diversity in alternative procedures and investment in specialty equipment. The predominant shift towards capital equipment that can be used off label across procedure types is both limiting capital equipment sales and access to preferred treatment options in 2016.
Complete report available @ Japan Procedure Numbers for Gynecological Devices 2017 - MedPro
The assisted reproduction technology device market comprised 66.8% of the overall market for gynecological devices in 2016. The investment in cutting edge technology fueled by exponential patient demand has led to increasing patient growth across all five market segments. The treatment cycles covered in the ART market include IVF, ICSI and FER cycles. Additionally, the ART market is being heavily impacted by numerous mergers and acquisitions, creating monopolies on prices and market shares.
Japan has the highest rate for uterine fibroid embolization procedures worldwide. The preference for UFE is the most pronounced in Japan; however, this trend is true throughout Asia and Oceania. The influence of embolization technology and newly approved devices is carrying over into the field of gynecology. The markets for endometrial resection and the emergence of endometrial ablation are projected to cannibalize UFE procedures over the forecast period.
Scope
2013-2023
2013-2023
Companies Mentioned
Kitazato Cook Medical Olympus Cooper Surgical Boston Scientific Vitrolife Irvine Scientific Naka Medical Johnson & Johnson Karl Storz Vitromed Rocket Medical Medi-Con International Carl Zeiss Sankyo Medical Pentax Life Global (IVF Online) Astec Bio The Pipette Company Esco Global Stryker Richard Wolf Merit Medical Systems BTG Leica Medtronic Others include: Nidacon Medical, Reproline Medical, ThermoFisher, AngioDynamics, Welch Allyn, local competitors, etc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
No comments:
Post a Comment